UR9.F Clinuvel Pharmaceuticals Limited

Healthcare Biotechnology Frankfurt Exchange
4.58 EUR
Close of Nov 12, 2026
4.30 7.41
Market cap
EUR 231M
P/E
11.7x
P/B
1.37x
ROE
12.4%
Dividend yield
0.69%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is UR9.F undervalued?

Graham number
Price4.58
Graham value5.42
Discount15.5%

UR9.F trades 15.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Clinuvel Pharmaceuticals Limited fundamental analysis

No fundamental analysis for Clinuvel Pharmaceuticals Limited yet.

Clinuvel Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimu…

Full company profile